A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Development of the ulcerative colitis project PN-943 continues.
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.